What Populations Are Most at Risk for OPMD?
At a Glance
Oculopharyngeal Muscular Dystrophy (OPMD) is most common in individuals of French-Canadian, Bukharian Jewish, and New Mexican descent due to a genetic founder effect in the PABPN1 gene. However, anyone can inherit the mutation and develop OPMD regardless of their ethnic background.
In this answer
3 sections
If your doctor asked about French-Canadian or Bukharian Jewish ancestry while discussing Oculopharyngeal Muscular Dystrophy (OPMD), it is because the condition is significantly more common in these specific populations [1]. While OPMD affects people worldwide at a rate of roughly 1 in 80,000, the genetic mutation responsible for the disease is found at much higher rates in individuals of French-Canadian (especially from Quebec) and Bukharian Jewish descent [2][1]. This concentration is due to a genetic phenomenon known as the “founder effect.”
What is the Founder Effect?
A founder effect happens when a small group of individuals breaks off from a larger population to establish a new, isolated community. If one of those original “founders” carries a specific genetic mutation, that mutation is passed down to their descendants. Over generations, as the community grows but remains relatively tight-knit, the mutation becomes far more common in that specific group than it is in the general public [1].
Populations With Higher Risk
OPMD is primarily caused by a mutation—specifically, an expansion of repeating genetic code—in the PABPN1 gene [3][4]. Historically, this specific genetic change became concentrated in a few distinct groups:
- French-Canadians: The condition is highly prevalent in this population, particularly among families with deep roots in Quebec, Canada [2].
- Bukharian Jews: People of Bukharian Jewish descent, whose ancestors historically lived in Central Asia, are considered a high-risk group for carrying specific PABPN1 mutations [5].
- New Mexican Communities: OPMD has also been noted at higher rates within some long-established families in the southwestern United States, particularly New Mexico [1].
Because of these known genetic clusters, doctors will often ask about your family’s geographic and ethnic background. This helps them determine whether genetic counseling and testing for the PABPN1 mutation might be necessary [5]. If a mutation is found, its specific size can also influence how early symptoms appear and how severe they are [6][7].
Can Anyone Get OPMD?
Yes. It is crucial to understand that OPMD is not restricted to these specific ancestral groups. While the founder effect makes the condition more concentrated in certain communities, the genetic mutation can happen in anyone [8].
Cases of OPMD have been documented globally, including in individuals of Japanese, Italian, Filipino, and South African descent [9][10][11]. Regardless of your ethnic background, the core symptoms of the disease—such as late-onset drooping eyelids (ptosis), difficulty swallowing (dysphagia), and muscle weakness—remain largely the same [2][10]. Rare, atypical cases and recessive inheritance forms also exist, making proper genetic screening essential for anyone displaying symptoms, regardless of their family’s origins [2][10].
Common questions in this guide
What populations are at the highest risk for OPMD?
Why does my ancestry affect my risk for Oculopharyngeal Muscular Dystrophy?
Can I get OPMD if I do not have French-Canadian or Bukharian Jewish heritage?
Should my family members be tested for the PABPN1 gene mutation?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my specific ancestry change how we should approach my genetic testing or treatment plan?
- 2.Should my children or other blood relatives be tested for the PABPN1 gene mutation?
- 3.Based on my test results, what are the chances of passing this genetic mutation to my children?
- 4.Can you refer me to a genetic counselor to help my family understand our specific risks?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Oculopharyngeal Muscular Dystrophy, an Often Misdiagnosed Neuromuscular Disorder: A Southern California Experience.
Goyal NA, Mozaffar T, Chui LA
Journal of clinical neuromuscular disease 2019; (21(2)):61-68 doi:10.1097/CND.0000000000000271.
PMID: 31743248 - 2
Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD).
Harish P, Malerba A, Lu-Nguyen N, et al.
Journal of cachexia, sarcopenia and muscle 2019; (10(5)):1016-1026 doi:10.1002/jcsm.12438.
PMID: 31066242 - 3
[Haplotype Analysis of Oculopharyngeal Muscular Dystrophy (OPMD) Locus in Yakutia].
Marusin AV, Kurtanov KhA, Maksimova NR, et al.
Genetika 2016; (52(3)):376-84.
PMID: 27281858 - 4
A Case of Oculopharyngeal Muscular Dystrophy Caused by a Novel PABPN1 c.34G > T (p.Gly12Trp) Point Mutation without Polyalanine Expansion.
Takahashi Y, Morimoto N, Nada T, et al.
Journal of neuromuscular diseases 2023; (10(3)):459-463 doi:10.3233/JND-221669.
PMID: 36847015 - 5
Oculopharyngeal Muscular Dystrophy and Inherited Retinal Dystrophy in Bukhara Jews Due to Linked Mutations in the PABPN1 and NRL Genes.
Braverman I, Blumen SC, Newman H, et al.
Genetic testing and molecular biomarkers 2017; (21(7)):450-453 doi:10.1089/gtmb.2016.0429.
PMID: 28590779 - 6
Correlation between PABPN1 genotype and disease severity in oculopharyngeal muscular dystrophy.
Richard P, Trollet C, Stojkovic T, et al.
Neurology 2017; (88(4)):359-365 doi:10.1212/WNL.0000000000003554.
PMID: 28011929 - 7
Clinical and genetic features of a large homogeneous cohort of oculopharyngeal muscular dystrophy patients from the Canary Islands.
Alonso-Pérez J, de León Hernández JC, Pérez-Pérez H, et al.
European journal of neurology 2022; (29(5)):1488-1495 doi:10.1111/ene.15252.
PMID: 35112761 - 8
A South African family with oculopharyngeal muscular dystrophy: Clinical and molecular genetic characteristics.
Schutte CM, Dorfling CM, van Coller R, et al.
South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 2015; (105(7)):540-3 doi:10.7196/SAMJnew.7880.
PMID: 26428746 - 9
Glossoptosis After Tracheal Extubation in a Patient With Oculopharyngeal Muscular Dystrophy: A Case Report.
Akizawa C, Tokumine J, Motoyama H, et al.
Cureus 2025; (17(10)):e93696 doi:10.7759/cureus.93696.
PMID: 41181735 - 10
Dropped-head in recessive oculopharyngeal muscular dystrophy.
Garibaldi M, Pennisi EM, Bruttini M, et al.
Neuromuscular disorders : NMD 2015; (25(11)):869-72.
PMID: 26494409 - 11
Choked: A Case Report of Oculopharyngeal Muscular Dystrophy Mimicking Hypothyroidism From the Philippines.
Infante JM, Nepomuceno BL
Cureus 2023; (15(6)):e41025 doi:10.7759/cureus.41025.
PMID: 37519616
This page is for informational purposes only and does not replace professional medical advice. Always consult your healthcare provider or a genetic counselor to understand your specific risks for OPMD.
Get notified when new evidence is published on Oculopharyngeal muscular dystrophy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.